Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Author: , AbeKoji, ArakiNobuyuki, AtsutaNaoki, FujitaKoji, FuruyaHirokazu, HatanakaYuki, HattoriNobutaka, IkedaKen, IshiharaTomohiko, IsoseSagiri, ItoHidefumi, IzumiYuishin, KagimuraTatsuo, KajiRyuji, KanaiKazuaki, KanoOsamu, KikuchiHitoshi, KoharaNobuo, KojimaYasuhiro, KomaiKiyonobu, KuwabaraSatoshi, KuzumeDaisuke, MaruyamaHirofumi, MiyamotoRyosuke, MoritaMitsuya, NagaiMakiko, NakayamaYoshiaki, NishinakaKazuto, NishiyamaKazutoshi, NodaKazuyuki, NoderaHiroyuki, NokiharaHiroshi, NomaKensuke, OdaMasaya, OkiRyosuke, OnoderaOsamu, SakaguchiSatoshi, SatoYasutaka, ShibuyaKazumoto, ShimizuToshio, ShimohamaShun, ShimohataTakayoshi, SobueGen, SonooMasahiro, TeramukaiSatoshi, TodaTatsushi, TsunemiTaiji, UrushitaniMakoto, YanagawaHiroaki

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized clinical trial evaluated the efficacy and safety of ultrahigh-dose methylcobalamin for early-stage amyotrophic lateral sclerosis (ALS). 130 patients were randomly assigned to receive either methylcobalamin or placebo. Methylcobalamin showed efficacy in slowing functional decline in patients with moderate progression rate and was well tolerated.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: The effectiveness of currently approved drugs for amyotrophic lateral sclerosis (ALS) is restricted; there is a need to develop further treatments. Initial studies have shown ultrahigh-dose methylcobalamin to be a promising agent. OBJECTIVE: To validate the efficacy and safety of ultrah...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086935/

データ提供：米国国立医学図書館（NLM）

A Glimpse into the Sands of Time: Ultrahigh-Dose Methylcobalamin in ALS

The world of amyotrophic lateral sclerosis (ALS) is a vast and challenging desert, where researchers are constantly searching for oases of hope. This study dives deep into the potential of ultrahigh-dose methylcobalamin, a promising agent that could help slow the progression of this devastating disease. Using a meticulously designed randomized clinical trial, the researchers sought to assess the efficacy and safety of this treatment in early-stage ALS patients. They discovered that this particular dose of methylcobalamin significantly slowed functional decline in these patients, providing a glimmer of hope for those struggling with the disease. The study also demonstrated that the treatment was safe for patients during the trial period.

A Ray of Hope in the Desert: Ultrahigh-Dose Methylcobalamin Shows Promise

The results suggest that ultrahigh-dose methylcobalamin could be a valuable tool in combating ALS. The drug's ability to slow the progression of the disease could improve patients' quality of life and potentially extend their lifespan. This finding is encouraging, as it provides evidence for a potentially effective treatment for a disease with limited options.

A Oasis in the ALS Desert: Navigating the Implications

The discovery of a safe and effective treatment for early-stage ALS is a significant breakthrough. However, it's important to remember that this is just one study, and further research is necessary to confirm these findings. The impact of this treatment on long-term outcomes and different stages of ALS remains to be explored. Nevertheless, this study offers a beacon of hope in the vast desert of ALS research, reminding us that even in the most challenging of circumstances, progress is possible.

Dr.Camel's Conclusion

This study is a camel's oasis in the desert of ALS research. It suggests that ultrahigh-dose methylcobalamin can provide a glimmer of hope by slowing functional decline in early-stage ALS patients. While we must continue to explore its long-term effects, this finding is a valuable step towards a brighter future for those living with ALS.

Date :
  1. Date Completed 2022-06-15
  2. Date Revised 2023-05-10
Further Info :

Pubmed ID

35532908

DOI: Digital Object Identifier

PMC9086935

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.